Quick Answer
FibroBiologics, Inc. reported Operating Income of -$16.65 million for fiscal year 2025.
FibroBiologics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$16.65M | -21.2% |
| 2024 | -$13.74M | -54.5% |
| 2023 | -$8.89M | -99.0% |
| 2022 | -$4.47M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.04M | -50.3% | -12.2% |
| June 30, 2025 | -$4.49M | -39.3% | +0.9% |
| March 31, 2025 | -$4.53M | -31.3% | -35.2% |
| September 30, 2024 | -$3.35M | -63.4% | -4.0% |
| June 30, 2024 | -$3.22M | -54.0% | +6.6% |
| March 31, 2024 | -$3.45M | -52.3% | -68.1% |
| September 30, 2023 | -$2.05M | — | +2.0% |
| June 30, 2023 | -$2.09M | — | +7.6% |
- FibroBiologics, Inc. showed a decrease of -21.2% in Operating Income compared to the prior fiscal year.
- Over the 2022–2025 period, FibroBiologics, Inc.’s operating income has declined by 272.7% (from -$4.47 million to -$16.65 million).
- The most recent figure is from FibroBiologics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: